Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer

Systemic cisplatin-based chemotherapy regimens are the gold standard in advanced bladder cancer. Gemcitabine plus cisplatin (GC) therapy has often been used, although there is no significant evidence that it is better than methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) therapy in neoadj...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 59(2013), 5 vom: 26. Mai, Seite 277-81
1. Verfasser: Kawamura, Norihiko (VerfasserIn)
Weitere Verfasser: Matsushita, Makoto, Okada, Takayuki, Ujike, Takeshi, Nin, Mikio, Tsujihata, Masao
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 2013
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Comparative Study English Abstract Journal Article Antibiotics, Antineoplastic Antimetabolites, Antineoplastic Antineoplastic Agents Antineoplastic Agents, Phytogenic Deoxycytidine 0W860991D6 Vinblastine mehr... 5V9KLZ54CY Doxorubicin 80168379AG Cisplatin Q20Q21Q62J Methotrexate YL5FZ2Y5U1 Gemcitabine
Beschreibung
Zusammenfassung:Systemic cisplatin-based chemotherapy regimens are the gold standard in advanced bladder cancer. Gemcitabine plus cisplatin (GC) therapy has often been used, although there is no significant evidence that it is better than methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) therapy in neoadjuvant chemotherapy. We retrospectively evaluated the relative efficacy of the two chemotherapeutic regimens in the management of muscle-invasive bladder cancer on patients who had had radical cystectomy for clinical stage T2-T4, N and, M0 bladder cancer. Fourteen patients (24.1%) and 44 (75.9%) patients were treated with GC and MVAC therapy, respectively. GC therapy was significantly more effective than MVAC therapy in pathological down-staging (to pT0) rate. On multivariate analysis, the choice of regimen (MVAC) was an independent predictor of the presence of residual cancer after a neoadjuvant chemotherapy. The clinical response to neoadjuvant GC therapy was superior to that to neoadjuvant MVAC therapy. Moreover, GC therapy was associated with less non-hematologic toxicity than MVAC therapy, especially with respect to the occurrence of nausea
Beschreibung:Date Completed 25.09.2013
Date Revised 07.12.2022
published: Print
Citation Status MEDLINE
ISSN:0018-1994